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INTRODUCTION 
Elevated low-density lipoprotein cholesterol (LDL-C) is one of 
the major cardiovascular risk factors, and remains a primary 
target in lipid lowering therapy. Statins have been proven to be 
the most effective medication to reduce LDL-C level and to 
further prevent cardiovascular disease (CVD). However, addi-
tional cardiovascular risk factors beyond LDL-C should be ad-
dressed, because a significant residual CVD risk was detected 
in patients achieving optimal LDL-C level by intensive statin 
therapy [1]. 
As a modifiable cardiovascular risk factor, hypertriglyceride-
mia is recently emerging as a reliable therapeutic target espe-
cially in Korea, where the prevalence of hypertriglyceridemia 
is greater than that of hypercholesterolemia [2]. Recent evi-
dence supports an independent association of triglyceride 
(TG) level with CVD after adjustment for conventional risk 
factors and high-density lipoprotein cholesterol (HDL-C) level 
[3,4]. Elevated TG level over 5 years increased the incidence of 
coronary heart disease (CHD), regardless of baseline TG level 
[4]. Among hospitalized patients with acute coronary syn-
drome, those with TG level >150 mg/dL and LDL-C level <70 
mg/dL exhibited a 15% higher CHD event rate than those with 
low TG level and high LDL-C level [5]. Particularly in patients 
with type 2 diabetes mellitus (DM), two large trials demon-
strated that a combination of statins with TG-lowering medi-
cation reduced CVD events in a subgroup of subjects with 
marked hypertriglyceridemia and low HDL-C level [6,7]. 
Therefore, recent guidelines emphasized the importance of 
non-HDL-C as a secondary target for preventing CVD in pa-
tients with mixed dyslipidemia who achieved LDL-C target [8-
10]. Thus, TG-lowering therapy might be beneficial as an add-
on to statin treatment in patients with well-controlled LDL-C, 
but high TG level. Among several treatment options to control 
the hypertriglyceridemia, omega-3 fatty acids (OM3-FAs) in-
duced a greater reduction of TG and were associated with few 
adverse effects when added to statins [11-13]. Thus, this phase 
III study was designed to assess the efficacy and tolerability of 
OM3-FAs 4,000 mg/day in combination with atorvastatin 20 
mg/day in patients with persistent hypertriglyceridemia at 




Study design and procedures 
This 8-week randomized, double-blind, placebo-controlled, 
parallel-group, and phase III multicenter study was conducted 
at 36 centers throughout Korea between May 4, 2016 and May 
16, 2017. Adult subjects aged 20 to 79 years with high CVD 
risk according to the Korean dyslipidemia guideline [9] were 
screened at the first visit. Participants were selected according 
to the following criteria: (1) fasting TG level ≥300 mg/dL with 
LDL-C level ≥100 mg/dL and <160 mg/dL for the subjects 
who were not taking statins for the last 4 weeks; (2) fasting TG 
level ≥200 mg/dL and <500 mg/dL with LDL-C level <110 
Background: Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced 
by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a 
secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 
fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia.
Methods: This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults 
with fasting triglyceride (TG) levels ≥200 and <500 mg/dL and LDL-C levels <110 mg/dL. Eligible subjects were randomized to 
ATOMEGA (OM3-FAs 4,000 mg plus atorvastatin calcium 20 mg) or atorvastatin 20 mg plus placebo groups. The primary effi-
cacy endpoints were the percent changes in TG and non-HDL-C levels from baseline at the end of treatment.
Results: After 8 weeks of treatment, the percent changes from baseline in TG (–29.8% vs. 3.6%, P<0.001) and non-HDL-C 
(–10.1% vs. 4.9%, P<0.001) levels were significantly greater in the ATOMEGA group (n=97) than in the atorvastatin group 
(n=103). Moreover, the proportion of total subjects reaching TG target of <200 mg/dL in the ATOMEGA group was significantly 
higher than that in the atorvastatin group (62.9% vs. 22.3%, P<0.001). The incidence of adverse events did not differ between the 
two groups. 
Conclusion: The addition of OM3-FAs to atorvastatin improved TG and non-HDL-C levels to a significant extent compared to 
atorvastatin alone in subjects with residual hypertriglyceridemia.
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mg/dL for the subjects who were taking statins for the last 4 
weeks; and (3) non-smoking during the study period. 
These subjects underwent a 4-week run-in period of open la-
bel atorvastatin 20 mg/day, and were scheduled for the second 
screening. The participants who were taking 20 mg/day of ator-
vastatin over 4 weeks could visit for the second screening with-
out a run-in period (Fig. 1). To be eligible for the second screen-
ing, the subjects should meet the following criteria: (1) residu-
al hypertriglyceridemia with fasting TG level ≥200 mg/dL 
and <500 mg/dL with LDL-C level <110 mg/dL; (2) decreased 
LDL-C level during the run-in period compared to that at the 
first screening, if subjects were not taking statins previously; 
and (3) an adherence rate of ≥80% for statin during the run-in 
period. All participants received dietary counseling for dyslip-
idemia based on the Korean dyslipidemia guideline during 
their screening visit [9]. The following exclusion criteria were 
applied: (1) a history of unstable angina, acute myocardial in-
farction (MI), coronary artery revascularization, including 
coronary artery bypass surgery, or transient ischemic attack or 
stroke 3 months prior to screening; (2) a history of operation 
for aortic aneurysm within 6 months prior to screening; (3) 
symptoms of unexplained myalgia or a diagnosis of myalgia or 
rhabdomyolysis at screening; (4) a history of pancreatitis prior 
to screening; (5) significant comorbid medical illness in car-
diovascular, hepatobiliary, neuropsychiatric, endocrine system 
that posed difficulties in continuing clinical trial and interpret-
ing test results; (6) a history of positive antibody to Human Im-
munodeficiency Virus (HIV)-1 or positive HIV test result; (7) a 
history of malignant tumor within 2 years, except for complete 
resolution of basal cell or squamous cell carcinoma; (8) the use 
of prohibited concomitant medications; (9) sex hormone re-
placement or use of oral contraceptives 2 months prior to 
screening or during clinical trial; (10) uncontrolled hyperten-
sion (systolic blood pressure [BP] ≥180 mm Hg and/or dia-
stolic BP ≥110 mm Hg); (11) serum creatinine level ≥2 times 
the upper limit of normal; (12) alanine aminotransferase 
(ALT) and/or aspartate aminotransferase levels ≥3 times the 
upper limit of normal; (13) creatine phosphokinase level five 
times the upper limit of normal; (14) a genetic disorder, in-
cluding galactose intolerance, Lapp lactase deficiency, or galac-
tose malabsorption; (15) allergy or hypersensitivity to the 
study medications; (16) drug or alcohol abuse within 2 years 
prior to screening; (17) pregnancy or breast-feeding at screen-
ing; (18) possible pregnancy or planning to be pregnant during 
clinical trial; (19) inclusion in another clinical trial 1 month 
prior to screening; (20) other conditions that were not appro-
priate for clinical trial. Finally, eligible subjects were randomly 
assigned in a 1:1 ratio to each of two groups (ATOMEGA or 
atorvastatin group) for 8 weeks. Individuals in the ATOMEGA 
group were prescribed four capsules of ATOMEGA that con-
tained OM3-FAs 1,000 mg plus atorvastatin calcium 5 mg and 
one tablet of placebo of atorvastatin 20 mg. The individuals in 
the atorvastatin group were prescribed four capsules of place-
bo (olive oil 1,000 mg) and one tablet of atorvastatin calcium 
20 mg (Fig. 1).
Study subjects 
Among the 558 screened subjects, 268 subjects entered the 
run-in period, and 215 subjects were randomly assigned to the 
treatment groups (105 subjects to the ATOMEGA group and 
Fig. 1. Study design. Adult subjects with high cardiovascular disease risk were screened, and eligible subjects underwent a 4-week 
run-in period of open label atorvastatin 20 mg/day, and were scheduled for a second screening. Enrolled subjects were randomly 
assigned in a 1:1 ratio to each of the two groups (ATOMEGA group or atorvastatin group) for 8 weeks of treatment. Individuals 
in ATOMEGA group were prescribed four capsules of ATOMEGA containing omega-3 fatty acids 1,000 mg plus atorvastatin cal-
cium 5 mg and one tablet of placebo of atorvastatin 20 mg/day. Individuals in the atorvastatin group were prescribed four cap-
sules of placebo (olive oil 1,000 mg) and one tablet of atorvastatin calcium 20 mg.
Screening (Run-in)




ATOMEGA (K1106) 4 capsules+placebo (atorvastatin 20 mg) once
Placebo (ATOMEGA) 4 capsules+atorvastatin 20 mg once
Treatment visit Last visit
Treatment
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110 subjects to the atorvastatin group). From the randomized 
population, eight subjects in the ATOMEGA group and seven 
subjects in the atorvastatin group were excluded from safety 
set due to violation of eligibility criteria or incomplete mea-
surement of TG or non-HDL-C level. Finally, 200 subjects (97 
subjects in the ATOMEGA group and 103 subjects in the ator-
vastatin group) were included in full analysis set population for 
evaluating the efficacy endpoints (Supplementary Fig. 1). 
Study endpoints
The primary efficacy endpoints were the percentage changes in 
TG and non-HDL-C levels from baseline after 8 weeks of treat-
ment. The secondary efficacy endpoints included the percent-
age changes in other lipid parameters, such as total cholesterol 
(TC), HDL-C, very low density lipoprotein cholesterol (VLDL-
C), apolipoprotein (Apo) A-I, and Apo B, from baseline to the 
end of the treatment. Lipid samples, including LDL-C, were 
measured by the laboratories of each hospital using standard 
procedures. 
Safety was assessed by monitoring adverse events (AEs), lab-
oratory parameters, electrocardiograms, and vital signs, in ad-
dition to physical examinations. AEs were defined as occurred, 
worsened, or became serious during the study period, and in-
cluded all unintended consequences of the individual receiving 
treatment, regardless of the causality. AEs were categorized as 
definitely related, probably related, possibly related, probably 
not related, definitely not related, and with unknown relation-
ship to the study drug. 
Definitions 
Hypertension was defined as systolic BP/diastolic BP ≥140/90 
mm Hg and/or a previous diagnosis of hypertension in the 
self-report. DM was defined as fasting plasma glucose (FPG) 
level ≥126 mg/dL, hemoglobin A1c (HbA1c) ≥6.5%, and/or 
previous diagnosis of DM in the self-report. A 10-year CHD 
risk was estimated by the National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP-ATP III) Framingham 
risk score [14]. The categories of age, sex, TC, HDL-C, smok-
ing status, systolic BP, and antihypertensive medication use 
were considered and calculated using a downloadable spread-
sheet calculator. 
Statistical analyses 
A previous study calculated that a sample size of 214 patients 
(107 patients in each treatment group) has 90% power to de-
tect a difference of 7.9% (treatment group) and 1.5% (control 
group) in mean percent change in non-LDL-C at week 8 of 
treatment with 5% two-sided significance level, assuming a 
common standard deviation of 14.4% (treatment group) and 
11.2% (control group) in patients having an evaluable primary 
endpoint [11].
Continuous variables were presented as mean±standard de-
viation (SD) if normally distributed, or as median (25th to 75th 
percentile) if not normally distributed. The comparison of the 
two groups was performed by using t-test or Mann-Whitney U 
test. The outcomes of the two groups were compared accord-
ing to several subgroups. Categorical variables were expressed 
as numbers and percentages, and analyzed by chi-square test. 
Univariate and multivariate linear regression analyses were 
performed to detect clinical factors associated with greater ef-
fect of OM3-FAs in lowering TG and non-HDL-C levels.
The intention-to-treat population included all randomized 
patients. Efficacy analyses involved full analysis set population 
who received at least one dose of the study drug and provided 
at least one post-randomized blood sample. The last observa-
tion carried forward method was used to impute missing non-
baseline data for patients who did not complete the treatment 
period. Safety analyses were performed in the safety set popu-
lation who received at least one dose of double-blind study 
drug and underwent at least one safety assessment after ran-
domization. The chi-square test was used to compare the inci-
dence of AEs between the two groups. 
Ethical approval and consent to participate
All procedures involving human participants performed in 
this study were in accordance with the ethical standards of the 
relevant institutional and/or national research committees and 
with the 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards. The study protocol was ap-
proved by the Institutional Review Board (IRB number: Ap-
pendix 1) or ethics committee at each participating center, and 
all patients provided written informed consent. This study was 




Baseline characteristics of the study subjects were generally 
similar, regardless of treatment allocation (Table 1). Enrolled 
subjects were middle-aged with a mean age of 58.3 years, obese 
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with a mean body mass index (BMI) of 27.2 kg/m2, and with a 
high 10-year CHD risk score (mean 9.9%). The proportion of 
patients with DM were not different between the ATOMEGA 
and atorvastatin groups (89.7% vs. 86.4%, P=0.478). No sig-
nificant differences in any variable, including baseline lipid pa-
rameters, were found between the two groups. 
Changes in lipid and lipoprotein levels after 8 weeks of 
treatment
ATOMEGA group achieved significant reductions in TG and 
non-HDL-C levels after the 8-week treatment compared to 
baseline, while atorvastatin group showed no change in TG 
level and a slight increase in non-HDL-C level (Table 2). Per-
cent changes in TG (–29.8% vs. 3.6%, P<0.001) and non-
HDL-C level (–10.1% vs. 4.9%, P<0.001) were significantly de-
creased in the ATOMEGA group than in the atorvastatin 
group (Table 2, Fig. 2). 
Among other lipid parameters, significant decreases in TC, 
VLDL-C, Apo A1, and Apo B levels in addition to a significant 
increase in HDL-C level were detected in the ATOMEGA 
group after 8 weeks of treatment compared to baseline (Table 
2). Moreover, the decreases in TC, VLDL-C, Apo A1, and Apo 
B levels were significantly greater in the ATOMEGA group 
than in the atorvastatin group. However, the percent change in 
LDL-C and HDL-C levels after 8 weeks of treatment did not 
show a significant difference between the two groups (Table 2, 
Fig. 2). In addition, the proportion of total subjects reaching 
TG target of <200 mg/dL after treatment was significantly 
higher in the ATOMEGA group than in the atorvastatin group 
(62.9% vs. 22.3%, P<0.001) (Supplementary Fig. 2A), and it 
Table 1. Baseline characteristics of the subjects 
Characteristic ATOMEGA (n=97) Atorvastatin (n=103) P value
Age, yr 58.7±10.1 58.0±11.4 0.679
Male sex 64 (66.0) 65 (63.1) 0.673
Body mass index, kg/m2 27.3±3.5 27.0±3.4 0.551
Prevalence of hypertension 80 (82.5) 84 (81.6) 0.866
Prevalence of diabetes 87 (89.7) 89 (86.4) 0.478
Systolic blood pressure, mm Hg 129.8±13.0 129.6±11.7 0.922
Diastolic blood pressure, mm Hg 81.2±9.3 81.7±8.5 0.707
Estimated GFR, mL/min/1.73 cm2 84.2±17.9 87.4±18.7 0.213
Fasting plasma glucose, mg/dL 141.1±53.0 132.3±36.9 0.177
Glycosylated hemoglobin, % 7.4±1.3 7.2±1.2 0.212
Lipid profiles, mg/dL
   Triglycerides    298.5±71.2 293.0±75.7 0.601
   Non-HDL-C 116.1±21.7 111.6±19.7 0.131
   TC 153.5±22.6 151.0±21.6 0.424
   LDL-C 77.1±20.1 75.7±18.7 0.619
   HDL-C 37.4±8.6 39.4±8.9 0.119
   VLDL-C 39.0±12.6 35.9±12.6 0.086
   Apo A1   127.0±20.2 132.6±21.8 0.062
   Apo B 81.9±16.9 82.4±15.7 0.832
Current smoker 30 (30.9) 21 (20.4) 0.088
Any use of alcohol 45 (46.4) 52 (50.5) 0.565
10-Year risk score for CHD, % 10.3±7.2 8.7±7.1 0.114
Previous use of statin 95 (97.9) 99 (96.1) 0.453
Values are presented as mean±standard deviation or number (%).
GFR, glomerular filtration rate; HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; 
VLDL-C, very low density lipoprotein cholesterol; Apo, apolipoprotein; CHD, coronary heart disease. 
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remained higher in the ATOMEGA group, both in men and in 
women (Supplementary Fig. 2B). 
Changes in FPG and HbA1c levels after 8 weeks of treatment
The percent change in FPG level and HbA1c after 8 weeks of 
treatment did not differ between ATOMEGA group (n=95) 
and atorvastatin group (n=96) (Supplementary Table 1). No 
difference in FPG and HbA1c levels between baseline and after 
8 weeks of treatment was found within each group, regardless 
of DM presence.
Subgroup analysis for the efficacy of ATOMEGA 
In subgroup analysis comparing percent changes in TG and non-
HDL-C levels according to age (≥65 years vs. <65 years), sex 
(male vs. female), BMI (≥25 kg/m2 vs. <25 kg/m2), presence of 
hypertension, presence of DM, estimated glomerular filtration 
Table 2. Lipid parameters at baseline and 8 weeks after treatment
Variable


































Triglycerides 298.5±71.2 210.6±117.1 –29.8±3.2 <0.001 293.0±75.7 299.3±133.9 3.6±3.7 0.593 <0.001
Non-HDL-C 116.1±21.7 103.6±28.6 –10.1±2.1 <0.001 111.6±19.7 115.8±28.6 4.9±2.3 0.095 <0.001
TC 153.5±22.6 143.1±28.7 –6.1±1.7 <0.001 151.0±21.6 155.8±29.9 3.8±1.7 0.061 <0.001
LDL-C 77.1±20.1 76.9±23.7 –1.9±2.8 0.913 75.7±18.7 79.2±23.3 6.5±2.5 0.055 0.226
HDL-C 37.4±8.6 39.5±9.9 6.4±1.8 0.003 39.4±8.9 40.0±9.3 2.6±1.5 0.227 0.096
VLDL-C 39.0±12.6 26.8±15.7 –30.1±3.5 <0.001 35.9±12.6 36.6±19.3 4.9±4.4 0.671 <0.001
Apo A1 127.0±20.2 122.0±20.0 –3.2±1.3 0.005 132.6±21.8 133.3±23.5 1.0±1.2 0.678 0.016
Apo B 81.9±16.9 78.9±20.4 –3.1±1.9 0.059 82.4±15.7 83.7±18.5 3.0±2.0 0.446 0.033
SD, standard deviation; SEM, standard error of the mean; HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low densi-
ty lipoprotein cholesterol; VLDL-C, very low density lipoprotein cholesterol; Apo, apolipoprotein.
Fig. 2. Percent change in lipid parameters from baseline after 8 weeks of treatment. Black bar represents the change in lipid pa-
rameters in the ATOMEGA group, while white vertical rectangle represents the change in lipid parameters in the atorvastatin 
group. TG, triglyceride; HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; LDL-C, low density lipoprotein cho-
lesterol; VLDL-C, very low density lipoprotein cholesterol; Apo A, apolipoprotein A; Apo B, apolipoprotein B. aP<0.05, bP<0.001 
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rate (eGFR) (≥60 mL/min/1.73 m2 vs. <60 mL/min/1.73 m2), 
and 10-year CHD risk (≥10% vs. <10%), ATOMEGA showed 
greater lowering effects on both TG and non-HDL-C levels af-
ter 8 weeks of treatment than atorvastatin in each subgroup, 
except in subjects without DM (Fig. 3). Both ATOMEGA and 
atorvastatin decreased TG (–16.9%±41.6% vs. –14.0%±30.6%, 
P=0.847) and non-HDL-C levels (–1.3%±30.0% vs. –7.1%± 
13.1%, P=0.524) with a similar extent in subjects without DM 
(Fig. 3). However, only ATOMEGA significantly reduced TG 
(–31.3%±29.8%) and non-HDL-C levels (–11.1%±19.6%) in 
Fig. 3. Comparison of triglyceride (TG) and non-high density lipoprotein cholesterol (non-HDL-C) lowering efficacy between 
ATOMEGA group (black bar) and atorvastatin group (white bar) in various subgroups. BMI, body mass index; eGFR, estimated 
glomerular filtration rate; CHD, coronary heart disease. aP<0.05, bP<0.01, cP<0.001 for the difference between the two groups.
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subjects with DM after 8 weeks of treatment, while atorvastatin 
slightly increased TG (6.4%±38.0%) and non-HDL-C levels 
(6.7%±23.9%) compared to baseline (Fig. 3).
Clinical factors affecting reduction in TG or non-HDL-C 
concentration by adding OM3-FAs
In univariate linear regression analysis, only higher FPG level 
was significantly associated with a reduction in TG level (β= 
4.03, P=0.045). However, this modest association disappeared 
after adjustment for age, sex, BMI, and baseline TG level in 
multivariate linear regression analysis (Table 3). Conversely, 
only higher baseline non-HDL-C level was positively associat-
ed with a reduction in non-HDL-C level in the univariate 
model (β=2.25, P=0.042); however, this association also lost 
statistical significance after adjustment for age, sex, BMI, and 
FPG level (Table 3).
Safety analyses 
The proportion of AEs (15.2% vs. 11.8%, P=0.463) and serious 
AEs (1.9% vs. 0.9%, P=0.615) did not differ between the ATO-
MEGA and atorvastatin groups (Supplementary Table 2). Two 
serious AEs in the ATOMEGA group were upper limb fracture 
(n=1, 0.95%) and hyperglycemia (n=1, 0.95%). Serum ALT 
level of the ATOMEGA group was significantly higher than 
that of the atorvastatin group, but was within the normal refer-
ence range. A mild increase in creatine phosphokinase level 
(less than three times the upper limit of the normal range) was 
only observed in the atorvastatin group (P=0.024) and was re-
Table 3. Clinical factors affecting reduction in triglycerides or non-HDL-C concentration by adding omega-3 fatty acid
Variable
Univariate Multivariate
β (95% CI) P value β (95% CI) P value 
Reduction of TG, mg/dL
   Age (by 10-year increment) 6.52 (–14.65 to 27.70) 0.542 0.93 (–23.20 to 22.40)a 0.936
   Female sex 20.53 (–24.08 to 65.15) 0.363 19.72 (–21.78 to 23.63)a 0.392
   BMI (by 1 kg/m2 increment) –4.10 (–10.20 to 2.01) 0.186 –3.67 (–10.15 to 2.81)a 0.264
   Presence of hypertension –4.56 (–60.39 to 51.28) 0.872
   Current smoking –5.68 (–51.60 to 40.24) 0.807
   Current drinking of alcohol –26.55 (–68.77 to 15.68) 0.215
   HbA1c (by 1% increment) 13.69 (–2.22 to 29.60) 0.091
   FPG (by 10 mg/dL increment) 4.03 (0.09 to 7.98) 0.045 3.25 (–0.82 to 7.31)a 0.116
   eGFR (by 10 mL/min/1.73 m2 increment) –3.31 (–15.23 to 8.61) 0.583
   Baseline TG (by 10 mg/dL increment) 2.31 (–0.65 to 5.25) 0.125 2.11 (–0.90 to 5.12)a 0.168
Reduction of non-HDL-C, mg/dL
   Age (by 10-year increment) –0.17 (–4.96 to 4.62) 0.944 –0.04 (–5.24 to 5.15)b 0.987
   Female sex 5.32 (–4.73 to 15.36) 0.296 3.30 (–7.30 to 13.90)b 0.538
   BMI (by 1 kg/m2 increment) 0.17 (–1.22 to 1.56) 0.814 0.19 (–1.28 to 1.67)b 0.795
   Presence of hypertension –6.62 (–19.14 to 5.90) 0.296
   Current smoking 1.02 (–9.34 to 11.37) 0.846
   Current drinking of alcohol –8.34 (–17.79 to 1.11) 0.083
   HbA1c (by 1% increment) 2.99 (–0.60 to 6.58) 0.102 
   FPG (by 10 mg/dL increment) 0.43 (–0.48 to 1.33) 0.352 0.48 (–0.44 to 1.39)b 0.303
   eGFR (by 10 mL/min/1.73 m2 increment) –0.15 (–2.84 to 2.54) 0.913
   Baseline non-HDL-C (by 10 mg/dL increment) 2.25 (0.09 to 4.42) 0.042 2.13 (0.13 to 4.40)b 0.065
HDL-C, high density lipoprotein cholesterol; CI, confidence interval; TG, triglyceride; BMI, body mass index; HbA1c, hemoglobin A1c; FPG, 
fasting plasma glucose; eGFR, estimated glomerular filtration rate.
aMultivariate model was adjusted for age, sex, BMI, FPG, and baseline TG level, bMultivariate model was adjusted for age, sex, BMI, FPG, and 
baseline non-HDL-C level. 
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ported as adverse drug reaction. 
 
DISCUSSION 
This study demonstrated that the combination of OM3-FAs 
4,000 mg/day and atorvastatin 20 mg/day in patients with re-
sidual hypertriglyceridemia resulted in significantly greater 
decreases in TG and non-HDL-C levels, compared to atorvas-
tatin 20 mg/day monotherapy. These prominent TG and non-
HDL-C lowering effects in ATOMEGA group were consistent 
regardless of age, sex, BMI, presence of hypertension, eGFR, 
and CHD risk. However, a greater decrease in TG and non-
HDL-C levels in the ATOMEGA group was only found in sub-
jects with DM. Finally, no significant differences in the inci-
dence and profile of AEs were observed between the ATOME-
GA and atorvastatin groups. 
The residual risk of atherosclerotic cardiovascular disease 
(ASCVD) remains high despite statin treatment, and the pres-
ence of hypertriglyceridemia was found to be a potent predic-
tor for residual ASCVD risk, even in the subjects with LDL-C 
<100 mg/dL [15]. This is related to the less robust effects of 
statins on TG and cholesterol carried by TG-rich lipoproteins, 
such as VLDL, intermediate density lipoproteins, and chylo-
microns [16]. Achieved non-HDL-C (<100 mg/dL) and TG 
(<200 mg/dL) levels were found to modulate plaque progres-
sion-regression rates in patients with achieved LDL-C level 
<70 mg/dL [17]. Although potential effect of TG-lowering 
treatment on CVD risk showed mixed results [9], a meta-anal-
ysis of 14 statin trials suggested that the relative CHD risk de-
creases by approximately 1% for every 1% reduction in non-
HDL-C level [18]. Therefore, many recent guidelines recom-
mended non-HDL-C as the secondary target for preventing 
CVD in patients with mixed dyslipidemia who achieved LDL-
C target goal [8-10].
Randomized controlled trials on OM3-FAs as monotherapy 
or as an adjunct to statin therapy supported the efficacy of 
OM3-FAs for reducing TG or non-HDL-C levels in individuals 
with hypertriglyceridemia or mixed dyslipidemia [11,12,19-
23]. Similar to our results, Combination of Prescription Ome-
ga-3 with Simvastatin (COMBOS) study demonstrated that the 
reduction in TG (–29.5% vs. –6.3%) and non-HDL-C (–9.0% 
vs. –2.2%) levels were significantly greater in subjects that re-
ceived 4,000 mg/day of OM3-FAs in addition to 40 mg/day of 
simvastatin, compared to simvastatin alone [11]. Moreover, a 
combination of 4,000 mg/day of OM3-FAs and 20 mg/day of 
rosuvastatin had a greater reduction in TG (–26.3% vs. –11.4%) 
and non-HDL-C (–10.7% vs. –2.2%) levels after 8 weeks of 
treatment compared to rosuvastatin alone [12]. However, con-
trary to our data, TG-lowering efficacy was significant regard-
less of DM presence, while non-HDL-C level was significantly 
decreased only in subjects with DM when OM3-FAs was add-
ed to statin in the aforementioned study on rosuvastatin [12]. 
In this study, TG and non-HDL-C lowering effects were more 
evident in subjects with DM compared to those without, when 
OM3-FAs were added to atorvastatin. While both combination 
therapy and atorvastatin alone reduced TG and non-HDL-C 
levels in subjects without DM, only the combination therapy 
was effective for lowering them in subjects with DM. This find-
ing suggested that the additional TG-lowering treatment might 
be needed to reduce TG and non-HDL-C levels in subjects 
with DM. 
As a possible explanation, diabetic dyslipidemia is character-
ized by high TG and decreased HDL-C levels even before the 
onset of clinically relevant hyperglycemia [24], and a higher 
baseline TG or non-HDL-C level is more likely to be decreased 
by treatment [12]. In fact, a higher FPG level was positively as-
sociated with TG reduction, and a higher baseline non-HDL-
C level was positively associated with non-HDL-C reduction 
in this study. Another explanation can be that the effect of 
OM3-FAs might be associated with the improvement of insu-
lin resistance. The OM3-FA treatment increased insulin sensi-
tivity in subjects with polycystic ovary syndrome [25], non-al-
coholic fatty liver disease [26], and type 2 DM [27]. The mech-
anism of this effect of OM3-FAs on the insulin resistance has 
been suggested to be the OM3-FA-induced modulation of mi-
tochondrial biogenesis and endoplasmic reticulum stress in 
order to reduce reactive oxygen species production and activa-
tion of inflammatory pathways [28], rather than direct regula-
tion of body weight or hyperglycemia [29]. Therefore, the 
prominent TG and non-HDL-C lowering effects in patients 
with DM from our study were possibly mediated by the im-
provement of insulin resistance. However, the parameters of 
insulin resistance could not be analyzed due to the lack of in-
sulin data. 
The proposed TG-lowering mechanisms of OM3-FAs were 
reduced hepatic production of TG-rich VLDL particles and 
increased rate of conversion of VLDL to LDL particles [30], 
while atorvastatin was found to decrease VLDL-TG concen-
tration by increasing VLDL-TG fractional catabolic rate [20]. 
Since statins affect lipid metabolism primarily by inhibiting the 
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cholesterol biosynthesis, which in turn increases the number 
of hepatic Apo B receptors, the clearance of all Apo B-contain-
ing LDL and VLDL is accelerated when OM3-FAs are co-ad-
ministrated [31]. Beyond the additive effect on TG lowering, 
some evidence suggests a synergetic effect of OM3-FAs and 
statin treatment on the metabolic profiles, since a combination 
of eicosapentaenoic acid (EPA) and lovastatin enhanced the reg-
ulatory effects on the gene expression of 3-hydroxy-3-methylgl-
utaryl coenzyme A reductase and LDL receptor in the HepG2 
cell line [32]. EPA potentiates peroxisome proliferator activat-
ed receptor-alpha effect, and consequently decreases hepatic li-
pogenesis [33]. Docosahexaenoic acid (DHA) not only en-
hances VLDL lipolysis, resulting in a greater conversion to LDL, 
but also increases the levels of HDL-C and larger, more buoy-
ant LDL particles [33]. A combination of pitavastatin, which 
has a potent anti-inflammatory effect, and EPA, which has a 
potent suppressive effect on vascular smooth muscle cell acti-
vation, compensates their weak effectiveness on plaque forma-
tion, and synergistically produces a favorable effect on athero-
sclerosis [34]. 
Although adding OM3-FAs to statin leads to significant re-
ductions in TG and non-HDL-C levels, the primary and sec-
ondary prevention trials of combination therapy have general-
ly show mixed effects on CVD [35]. The Japan EPA Lipid In-
tervention Study (JELIS) found that Japanese patients who re-
ceived both EPA and a statin had a significantly reduced risk of 
CVD, which was a composite of sudden cardiac death, MI, un-
stable angina, and coronary revascularization, compared to 
those treated with statin alone [36]. Reduction of Cardiovascu-
lar Events with Icosapent Ethyl–Intervention Trial (REDUCE-
IT) revealed that 4,000 mg/day of icosapent ethyl prevented a 
composite event of cardiovascular death, nonfatal MI, nonfatal 
stroke, coronary revascularization, or unstable angina in pa-
tients with established CVD or with diabetes and other risk 
factors, who had been receiving statin therapy [37]. Early initi-
ation of EPA (1,800 mg/day) with pitavastatin within 24-hour 
after percutaneous coronary intervention reduced cardiovas-
cular events occurring within 1 year, including death from a 
cardiovascular cause, nonfatal stroke, nonfatal MI, and revas-
cularization [38]. In contrast, an additional amount of OM3-
FAs did not affect the secondary prevention in statin users with 
previous MI compared to non-users [39]. Potential explana-
tions for these discrepant results might be the differences 
across the studies, such as the composition and dosage of 
OM3-FAs, duration of supplement administration, follow-up 
duration, study population, concurrent CVD treatment, and 
baseline TG levels.
Several limitations of this study should be acknowledged. 
First, this study mostly included middle-aged Asians with rela-
tively high CVD risk who needed statins. Therefore, it is diffi-
cult to extrapolate the current results to general population. 
Second, this study only demonstrated the short-term effect of 
adding OM3-FAs on lipid parameters. Furthermore, we could 
not investigate the association between these improvements in 
TG or non-HDL-C and future CVD prevention. Finally, TG 
and non-HDL-C lowering effects of adding OM3-FAs were 
more significant in subjects with DM, compared to subjects 
without DM. These differences were at some extent caused by 
the diabetic dyslipidemia characterized by high TG and non-
HDL-C levels, but could be also caused by the amelioration of 
insulin resistance which could not be assessed in this study, or 
by the small number of subjects without DM. 
In conclusion, over 8 weeks of treatment, 4,000 mg/day of 
OM3-FAs, when added to atorvastatin, significantly reduced 
TG and non-HDL-C levels compared with atorvastatin alone 
in subjects with well-controlled LDL-C levels and residual hy-
pertriglyceridemia. Particularly, in a post hoc analysis, the 
combination therapy conferred additional benefits to lowering 
TG and non-HDL-C levels in patients with DM. To prove clin-
ical evidence of a reduction of cardiovascular events with a 
combination of high dose OM3-FAs and statin, more studies 
are needed to elucidate the association between the improve-
ment of residual dyslipidemia and actual CVD prevention.
 
SUPPLEMENTARY MATERIALS
Supplementary materials related to this article can be found 
online at https://doi.org/10.4093/dmj.2018.0265.
CONFLICTS OF INTEREST
This work was financially supported by the Kuhnil Pharma-
ceutical Co., Ltd. (Seoul, Republic of Korea). The company 
funder had no role in the study design, in the collection, analy-
sis, and interpretation of data, in the writing of the manuscript, 
and in the decision to submit the article for publication.
AUTHOR CONTRIBUTIONS
Conception or design: I.K.J., M.K.L.
Jun JE, et al.
88 Diabetes Metab J 2020;44:78-90 https://e-dmj.org
Data acquisition: I.K.J., S.R.K., I.K.L., K.A.H., S.H.C., S.K.K., 
H.K.P., J.O.M., Y.L., H.S.K., S.H.K., H.C.K., S.A.L., C.B.L., 
K.M.C., S.H.H., W.Y.S., M.S.S., H.S.A., S.H.K., J.M.C., S.H.J., 
T.J.C., S.Y.K., K.H.W., D.B.K., J.H.L., M.K.L.
Analysis, or interpretation of data: J.E.J., I.K.J. 
Drafting the work or revising: J.E.J., I.K.J.    
Final approval of the manuscript: M.K.L.
ORCID
Ji Eun Jun  https://orcid.org/0000-0002-7204-4913
In-Kyung Jeong  https://orcid.org/0000-0001-7857-546X




1.  LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, 
Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, 
Wenger NK; Treating to New Targets (TNT) Investigators. In-
tensive lipid lowering with atorvastatin in patients with stable 
coronary disease. N Engl J Med 2005;352:1425-35.
2.  Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, Suh I. 
Prevalence of dyslipidemia among Korean adults: Korea Na-
tional Health and Nutrition Survey 1998-2005. Diabetes Metab 
J 2012;36:43-55. 
3.  Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, 
Kuivenhoven JA, Averna M, Boren J, Bruckert E, Catapano AL, 
Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Ma-
sana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, 
Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, 
Watts GF, Wiklund O; European Atherosclerosis Society Con-
sensus Panel. The polygenic nature of hypertriglyceridaemia: 
implications for definition, diagnosis, and management. Lan-
cet Diabetes Endocrinol 2014;2:655-66.
4.  Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, 
Henkin Y, Kochba I, Shai I. Changes in triglyceride levels and 
risk for coronary heart disease in young men. Ann Intern Med 
2007;147:377-85.
5.  Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald 
E; PROVE IT-TIMI 22 Investigators. Impact of triglyceride 
levels beyond low-density lipoprotein cholesterol after acute 
coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll 
Cardiol 2008;51:724-30.
6.  Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, 
Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) Study Investigators. 
Effects of fenofibrate treatment on cardiovascular disease risk 
in 9,795 individuals with type 2 diabetes and various compo-
nents of the metabolic syndrome: the Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) study. Diabetes Care 
2009;32:493-8. 
7.  Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: 
implications for treatment of dyslipidemia in type 2 diabetes 
mellitus. Clin Lipidol 2011;6:9-20.
8.  Catapano AL, Graham I, De Backer G, Wiklund O, Chapman 
MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen 
TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Versch-
uren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney 
MT; ESC Scientific Document Group. 2016 ESC/EAS guide-
lines for the management of dyslipidaemias. Eur Heart J 2016; 
37:2999-3058.
9.  Singh AK, Singh R. Triglyceride and cardiovascular risk: a crit-
ical appraisal. Indian J Endocrinol Metab 2016;20:418-28. 
10.  Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, 
Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, 
Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton 
EA, Fazio S, Davidson M. American Association of Clinical 
Endocrinologists and American College of Endocrinology 
guidelines for management of dyslipidemia and prevention of 
cardiovascular disease. Endocr Pract 2017;23:1-87. 
11.  Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shal-
witz RA, Ballantyne CM, Ginsberg HN; COMBination of pre-
scription Omega-3 with Simvastatin (COMBOS) Investigators. 
Efficacy and tolerability of adding prescription omega-3 fatty 
acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic pa-
tients: an 8-week, randomized, double-blind, placebo-con-
trolled study. Clin Ther 2007;29:1354-67. 
12.  Kim CH, Han KA, Yu J, Lee SH, Jeon HK, Kim SH, Kim SY, 
Han KH, Won K, Kim DB, Lee KJ, Min K, Byun DW, Lim SW, 
Ahn CW, Kim S, Hong YJ, Sung J, Hur SH, Hong SJ, Lim HS, 
Park IB, Kim IJ, Lee H, Kim HS. Efficacy and safety of adding 
omega-3 fatty acids in statin-treated patients with residual hy-
pertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN 
residual hyperTrIglyCeridemia), a randomized, double-blind, 
and placebo-controlled trial. Clin Ther 2018;40:83-94.
13.  Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Cur-
Atorvastatin with OM3-FA for hypertriglyceridemia
89Diabetes Metab J 2020;44:78-90 https://e-dmj.org
cio D, Johnson J, Kling D, Davidson MH. Effects of omega-3 
carboxylic acids on lipoprotein particles and other cardiovas-
cular risk markers in high-risk statin-treated patients with re-
sidual hypertriglyceridemia: a randomized, controlled, double-
blind trial. Lipids Health Dis 2015;14:98.
14.  Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz 
H, Kannel WB. Prediction of coronary heart disease using risk 
factor categories. Circulation 1998;97:1837-47.
15.  Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, 
Cushman M, Garg P, Sandfort V, Tsai M, Lopez JAG. Residual 
atherosclerotic cardiovascular disease risk in statin-treated 
adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Li-
pidol 2017;11:1223-33.
16.  Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deed-
wania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, 
Clark LT, Ballantyne CM. Results of the National Cholesterol 
Education (NCEP) Program Evaluation ProjecT Utilizing 
Novel E-Technology (NEPTUNE) II survey and implications 
for treatment under the recent NCEP Writing Group recom-
mendations. Am J Cardiol 2005;96:556-63.
17.  Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia 
SR, Tuzcu EM, Nicholls SJ. Non-HDL cholesterol and triglyc-
erides: implications for coronary atheroma progression and 
clinical events. Arterioscler Thromb Vasc Biol 2016;36:2220-8. 
18.  Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of 
the relationship between non-high-density lipoprotein choles-
terol reduction and coronary heart disease risk. J Am Coll Car-
diol 2009;53:316-22.
19.  Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, 
Machielse BN, Kling D, Davidson MH. Omega-3 free fatty ac-
ids for the treatment of severe hypertriglyceridemia: the Epa-
noVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J 
Clin Lipidol 2014;8:94-106.
20.  Ng TW, Ooi EM, Watts GF, Chan DC, Barrett PH. Atorvastatin 
plus omega-3 fatty acid ethyl ester decreases very-low-density 
lipoprotein triglyceride production in insulin resistant obese 
men. Diabetes Obes Metab 2014;16:519-26.
21.  Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, 
Braeckman RA, Soni PN. Efficacy and safety of eicosapentae-
noic acid ethyl ester (AMR101) therapy in statin-treated pa-
tients with persistent high triglycerides (from the ANCHOR 
study). Am J Cardiol 2012;110:984-92. 
22.  Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. 
Omega-3 fatty acid concentrates in the treatment of moderate 
hypertriglyceridemia. Expert Opin Pharmacother 2008;9: 
1237-48.
23.  Lee MW, Park JK, Hong JW, Kim KJ, Shin DY, Ahn CW, Song 
YD, Cho HK, Park SW, Lee EJ. Beneficial effects of omega-3 
fatty acids on low density lipoprotein particle size in patients 
with type 2 diabetes already under statin therapy. Diabetes 
Metab J 2013;37:207-11.
24.  Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. 
Cardiovascular risk factors in confirmed prediabetic individu-
als. Does the clock for coronary heart disease start ticking be-
fore the onset of clinical diabetes? JAMA 1990;263:2893-8.
25.  Yang K, Zeng L, Bao T, Ge J. Effectiveness of omega-3 fatty acid 
for polycystic ovary syndrome: a systematic review and meta-
analysis. Reprod Biol Endocrinol 2018;16:27. 
26.  Yan JH, Guan BJ, Gao HY, Peng XE. Omega-3 polyunsaturated 
fatty acid supplementation and non-alcoholic fatty liver dis-
ease: a meta-analysis of randomized controlled trials. Medicine 
(Baltimore) 2018;97:e12271.
27.  Jacobo-Cejudo MG, Valdes-Ramos R, Guadarrama-Lopez AL, 
Pardo-Morales RV, Martinez-Carrillo BE, Harbige LS. Effect of 
n-3 polyunsaturated fatty acid supplementation on metabolic 
and inflammatory biomarkers in type 2 diabetes mellitus pa-
tients. Nutrients 2017;9:E573. 
28.  Lepretti M, Martucciello S, Burgos Aceves MA, Putti R, Lio-
netti L. Omega-3 fatty acids and insulin resistance: focus on the 
regulation of mitochondria and endoplasmic reticulum stress. 
Nutrients 2018;10:E350.
29.  Chen C, Yu X, Shao S. Effects of omega-3 fatty acid supplemen-
tation on glucose control and lipid levels in type 2 diabetes: a 
meta-analysis. PLoS One 2015;10:e0139565.
30.  Maki KC, Dicklin MR, Lawless A, Reeves MS. Omega-3 fatty 
acids for the treatment of elevated triglycerides. Clin Lipidol 
2009;4:425-37.
31.  Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori 
TA. Regulatory effects of HMG CoA reductase inhibitor and 
fish oils on apolipoprotein B-100 kinetics in insulin-resistant 
obese male subjects with dyslipidemia. Diabetes 2002;51:2377-
86.
32.  Notarnicola M, Messa C, Refolo MG, Tutino V, Miccolis A, 
Caruso MG. Synergic effect of eicosapentaenoic acid and lov-
astatin on gene expression of HMGCoA reductase and LDL 
receptor in cultured HepG2 cells. Lipids Health Dis 2010;9:135.
33.  Davidson MH. Omega-3 fatty acids: new insights into the 
pharmacology and biology of docosahexaenoic acid, docosa-
pentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol 
2013;24:467-74.
Jun JE, et al.
90 Diabetes Metab J 2020;44:78-90 https://e-dmj.org
34.  Yuki T, Ii M, Nagatsuka T, Fujisaka T, Takeda Y, Hoshiga M, 
Imagawa A. Synergistic favorable effect of eicosapentaenoic 
acid and statin on atherosclerosis. Biomed Res 2018;29:2147-
52.
35.  Bowen KJ, Harris WS, Kris-Etherton PM. Omega-3 fatty acids 
and cardiovascular disease: are there benefits? Curr Treat Op-
tions Cardiovasc Med 2016;18:69.
36.  Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, 
Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, 
Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan 
EPA lipid intervention study (JELIS) Investigators. Effects of 
eicosapentaenoic acid on major coronary events in hypercho-
lesterolaemic patients (JELIS): a randomised open-label, blind-
ed endpoint analysis. Lancet 2007;369:1090-8.
37.  Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ket-
chum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif 
JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular 
risk reduction with icosapent ethyl for hypertriglyceridemia. N 
Engl J Med 2019;380:11-22.
38.  Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsuku-
da S, Yokohama F, Sogo M, Nishibe T, Matsuo N, Hirohata S, 
Ito H, Doi M. Early initiation of eicosapentaenoic acid and 
statin treatment is associated with better clinical outcomes 
than statin alone in patients with acute coronary syndromes: 
1-year outcomes of a randomized controlled study. Int J Cardi-
ol 2017;228:173-9.
39.  Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel 
OH, Kromhout D. Effects of n-3 fatty acids on major cardio-
vascular events in statin users and non-users with a history of 
myocardial infarction. Eur Heart J 2012;33:1582-8. 
